AbbVie Inc (ABBV)vsOwlet Inc (OWLT)
ABBV
AbbVie Inc
$227.23
+6.25%
HEALTHCARE · Cap: $391.50B
OWLT
Owlet Inc
$5.11
+3.23%
HEALTHCARE · Cap: $145.01M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 58576% more annual revenue ($62.82B vs $107.06M). ABBV leads profitability with a 5.8% profit margin vs -43.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
OWLT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Intrinsic value data unavailable for OWLT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : OWLT
OWLT has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while OWLT is a turnaround play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.86 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 28/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a pioneering leader in infant health technology, focused on enhancing the safety and wellness of newborns through its innovative monitoring solutions. Its flagship product, the Owlet Smart Sock, utilizes advanced pulse oximetry to deliver real-time insights into heart rates and oxygen levels, allowing parents to access crucial health data via mobile devices. As demand for pediatric health monitoring continues to rise, Owlet is strategically positioned to expand its product portfolio and strengthen its market presence. The company's commitment to delivering actionable health information and improving pediatric care aligns closely with institutional investors' interests in the rapidly evolving landscape of health technology.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?